Overview

Animal experiments are unavoidable during the drug development in preclinical phase. However, the responsibility of the use of animals in research mainly holds by the scientific staff and the ethical committees. Kineto Lab Ltd. has all the official and ethical licenses for animal (mouse) research.More details

Moreover, our staff is committed to observe the 3 Rs: replacement, refinement and reduction of animals in our research.More details

Company

Kineto Lab Ltd. is a privately owned Hungarian biotech research company founded by two biologists and one chemist in 2007 for testing and developing new antitumoral compounds.
Kineto Lab Ltd. currently employs 7 people in R&D professional. Kineto Lab Ltd. is fully equipped with instruments for in vitro cell-based analysis and for molecular techniques.

Kineto Lab Ltd. develops different methods for testing the possible effect of new agents on tumor cell migration, adhesion, matrix interaction, proliferation and programmed cell death (apoptosis).
Kineto Lab Ltd. has special expertise for testing these agents in different in vivo allo/iso- and xenograft models (i.e. subcutaneous tumor growth, orthotopic transplantation, metastasis models).
These techniques can be useful for detecting the possible effect of newly synthesized agents on tumor progression in preclinical investigation phase.

The company has extensive expertise in screening assays based on several successful projects completed for pharmaceutical, biotechnology, and academic institutions during the past years. Kineto Lab Ltd.’s expert team and partner laboratories manage the whole process of drug development from target specification and molecule design to in vivo animal models through HT in vitro screenings.

The company is committed to innovation and excellence, always seeking to exceed the expectations of partners.
The principal investigator on behalf of Kineto Lab Ltd. is Dr. József Tóvári. Dr. Tóvári is principal investigator of several basic research and R&D projects in the field of tumor progression.

Management

Attila Kigyós MSc. is the founder and Chief Executive Officer of Kineto Lab Research and Development Ltd.

In addition to acting as the managing director of the corporation, Attila is a seasoned professional with more than 2 decades of experience in the field of IT, biotechnology and drug discovery screening. Attila was selected as Chief Executive Officer based on his track record of leading Hungarian Biotech companies as executive manager, as well as strong executive and personal qualities.

He graduated at Eötvös Loránd University, Budapest in 1992 as a chemist. In his thesis he investigated different gas chromatography measurement methods for instrumental detection of volatile organic compounds released by plants.

In 1993 he participated in some intensive complementary courses to improve his faculty in developing new methods of gas chromatography measurement at the Eindhoven Technical University in The Netherlands.

From 1994 to 1997 he was a fellow and demonstrator in the Budapest University of Technology and Economics.

From 1998 he leads private companies as executive manager in IT and biotech fields as well.

Dr. József Tóvári, PhD, is the founder and Chief Scientific Officer of Kineto Lab Research and Development Ltd., head of the Departmant of Experimental Pharmacology, National Institute of Oncology, Budapest.

Dr. József Tóvari has a strong scientific experience in the field of translational applied research and development in oncology. He is co-author of 76 scientific publications; his cumulative impact factor is >220. He has >1400 independent citations. As Director of Research and Development for Kineto Lab Ltd., József Tóvari plays a cruical role in the design and management of the ongoing drug screening tests and services for companies at Kineto Lab Ltd..

After graduating as a biologist at the Eötvös Loránd University, Budapest in 1994, he continued his former research activities at the 1st Institute of Pathology and Experimental Cancer Research of the Semmelweis University of Medicine, Budapest. His main field of interest was the investigation of tumor metastasis including cell migration, invasion and interaction with extracellular matrices.

From the finishing of his PhD thesis in 1999 (title: Regulation of tumor cell – extracellular-matrix interaction in tumor metastasis process) he is working in the so called Metastasis Research Group in the National Institute of Oncology, Budapest and the National Korányi Institute of TB and Pulmonology, Budapest. He was visiting scientist in Finnland (University of Turku) and Switzerland (ETH) several times for various time periods with the help of joint research grants. He is member of three scientific associations (AACR, EACR, MOT) and supervises research works of three PhD. and several undergraduate students from the faculty of natural science or medicine. His scientific work was awarded with Young Scientist Award (2000), György Miklós Award (2005) and Bolyai Scholarship (2001-2004) of the Hungarian Academy of Sciences, EJC-Pharmamar Grant for young scientist (2004) and AACR-NCI International Investigator Opportunity Grants (2008). Dr. Tóvári holds lectures on cell motility and tumor angiogenesis for biology and physics students in Semmelweis University.

As a tumor biologist, Mihaly is a PhD candidate at the PhD school of pathological sciences, faculty of Oncology, Semmelweis University, Budapest. He is working in cell biology and tumor biology for over 9 years now. He was involved in multiple research topics such as mutation-based or therapy-induced chemoresistance of cancer, cell motility, cancer hypoxia, cancer cell metabolism, or tumor angiogenesis.

He is experienced in various in vitro techniques for cellular toxicity, DNA-, RNA-, or protein investigations, cell metabolism, and different imaging techniques. He is also skilled in diverse models of in vivo tumor and metastasis formation, cryopreservation, tumor biobanking. He is responsible for our PDTX archives and experiments, and participates in the coordination of many projects.

Ivan Randelovic MSc. is Biologist Researcher and Project Manager in Kineto Lab Research and Development Ltd, working on drug discovery screening and preclinical investigation and development of targeting cancer therapeutics.

He graduated at Belgrade University, Belgrade, Serbia, on Faculty of Biology, on Department of Molecular Biology and Physiology, module of Experimental Biomedicine in 2014. In his Master thesis he investigated anticancer activity and mechanism of actions of neutral and cationic Iridium (III) complexes with various sets of ligands.

From 2012. to 2014. he was a researcher in Cancer group at the Department of Immunology, on Institute for Biological Research „Siniša Stanković” (IBISS), University of Belgrade, Serbia, where he did experimental part of Master thesis, testing and evaluating new therapeutics with anticancer properties in the treatment of cancer, determining their molecular mechanisms of action and signaling pathways that modulate the response to cancer therapy, under project: “Molecular mechanisms of physiological and pharmacological control of inflammation and cancer” (No. 173013) funded by the Ministry of Education, Science and Technological Development of the Republic of Serbia.

From 2015. as Marie Skłodowska-Curie PhD fellow he works on National Institute of Oncology, Budapest, Hungary, at the Department of Experimental Pharmacology, under supervision of Dr. Jozsef Tóvári, investigating the effect of peptide-drug bio-conjugates on tumor growth and metastasis in vitro and in vivo, in frame of Marie Skodowska-Curie Innovative Training Network (ITN-ETN) “Peptide-Drug Conjugates for Targeted Delivery in Tumor Therapy – MAGICBULLET” project; Grant no: 642004.

In 2017. he was on secondment in Translational Cancer Biology lab on Biomedicum at Helsinki University, Helsinki, Finland, and in 2018. in Molecular Biology lab at Preclinical Research Department at the Research Center of Italfarmaco SpA, Milan, Italy.

From 2019. he is PhD candidate on Semmelweis University, Budapest, Hungary, at the Doctoral School of Pathological Sciences, on Experimental Oncology program.

He was Marie Skłodowska-Curie PhD study fellow in duration for 3 years, and holder of full tuition fee scholarship given by Ministry of Education, Science and Technological Development of the Republic of Serbia, and University of Belgrade for Bachelor and Master studies.

Contact us






I accept the privacy policy